Date: July 6th	
Your Name: Ya	ao Zhang
Manuscript Title: <u>F</u>	Phase II study of sequential chemoradiotherapy with L-asparaginase, dexamethasone, ifosfamide,
cisplatin, and etop	oside (DICE-L) in the early stage of extranodal natural killer (NK)/T-cell lymphoma
Manuscript numbe	er (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	xNone	
		Time frame: past	36 months
2	Grants or contracts from	x None	
	any entity (if not indicated in item #1 above).		
3	Royalties or licenses	xNone	
4	Consulting fees	x_None	

5	Payment or honoraria for	_xNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	_xNone		
	testimony			
7	Support for attending	_xNone		
	meetings and/or travel			
8	Patents planned, issued or	x None		
	pending			
9	Participation on a Data	x None		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	x None		
	in other board, society,			
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	_xNone		
12	Receipt of equipment,	xNone		
	materials, drugs, medical			
	writing, gifts or other			
	services			
13	Other financial or non-	xNone		
	financial interests			
		en		
Plea	Please summarize the above conflict of interest in the following box:			
N	one			
- 1				

Date: July 6th
Your Name: <u>Yizhen Liu</u>
Manuscript Title: Phase II study of sequential chemoradiotherapy with L-asparaginase, dexamethasone, ifosfamid
cisplatin, and etoposide (DICE-L) in the early stage of extranodal natural killer (NK)/T-cell lymphoma
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	xNone	pranning of the work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	xNone	
3	Royalties or licenses	x_None	
4	Consulting fees	x_None	

5	Payment or honoraria for	_xNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	_xNone		
	testimony			
7	Support for attending	_xNone		
	meetings and/or travel			
8	Patents planned, issued or	x None		
	pending			
9	Participation on a Data	x None		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	x None		
	in other board, society,			
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	_xNone		
12	Receipt of equipment,	xNone		
	materials, drugs, medical			
	writing, gifts or other			
	services			
13	Other financial or non-	xNone		
	financial interests			
		en		
Plea	Please summarize the above conflict of interest in the following box:			
N	one			
- 1				

Date: July 6th	
Your Name: Z	uguang Xia
Manuscript Title:	Phase II study of sequential chemoradiotherapy with L-asparaginase, dexamethasone, ifosfamide
cisplatin, and etop	poside (DICE-L) in the early stage of extranodal natural killer (NK)/T-cell lymphoma
Manuscript numb	er (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	x_None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.) No time limit for this item.		
	No time limit for this item.		
		c	
		Time frame: past	36 months
2	Grants or contracts from	xNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	x_None	
4	Consulting fees	x_None	

5	Payment or honoraria for	_xNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	_xNone		
	testimony			
7	Support for attending	_xNone		
	meetings and/or travel			
8	Patents planned, issued or	x None		
	pending			
9	Participation on a Data	x None		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	x None		
	in other board, society,			
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	_xNone		
12	Receipt of equipment,	xNone		
	materials, drugs, medical			
	writing, gifts or other			
	services			
13	Other financial or non-	xNone		
	financial interests			
		en		
Plea	Please summarize the above conflict of interest in the following box:			
N	one			
- 1				

Date: July 6th	
Your Name: <u>Jia Jin</u>	
Manuscript Title: Phase II study of sequential	I chemoradiotherapy with L-asparaginase, dexamethasone, ifosfamide
cisplatin, and etoposide (DICE-L) in the early	stage of extranodal natural killer (NK)/T-cell lymphoma
Manuscript number (if known):	-

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	xNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	xNone	
3	Royalties or licenses	xNone	
4	Consulting fees	x_None	

5	Payment or honoraria for	_xNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	_xNone		
	testimony			
7	Support for attending	_xNone		
	meetings and/or travel			
8	Patents planned, issued or	x None		
	pending			
9	Participation on a Data	x None		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	x None		
	in other board, society,			
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	_xNone		
12	Receipt of equipment,	xNone		
	materials, drugs, medical			
	writing, gifts or other			
	services			
13	Other financial or non-	xNone		
	financial interests			
		en		
Plea	Please summarize the above conflict of interest in the following box:			
N	one			
- 1				

Date: July 6th	
Your Name: Kai Xue	_
Manuscript Title: Phase II study of sequential chemoradiotherapy with L-asparaginase, dexamethasone, ifosfan	ıide
cisplatin, and etoposide (DICE-L) in the early stage of extranodal natural killer (NK)/T-cell lymphoma	
Manuscript number (if known):	_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	xNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	xNone	
3	Royalties or licenses	xNone	
4	Consulting fees	x_None	

5	Payment or honoraria for	_xNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	_xNone		
	testimony			
7	Support for attending	_xNone		
	meetings and/or travel			
8	Patents planned, issued or	x None		
	pending			
9	Participation on a Data	x None		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	x None		
	in other board, society,			
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	_xNone		
12	Receipt of equipment,	xNone		
	materials, drugs, medical			
	writing, gifts or other			
	services			
13	Other financial or non-	xNone		
	financial interests			
Plea	Please summarize the above conflict of interest in the following box:			
N	one			
- 1				

Date: July 6th
Your Name: Jiachen Wang
Manuscript Title: Phase II study of sequential chemoradiotherapy with L-asparaginase, dexamethasone, ifosfamid
cisplatin, and etoposide (DICE-L) in the early stage of extranodal natural killer (NK)/T-cell lymphoma
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	xNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	xNone	
3	Royalties or licenses	xNone	
4	Consulting fees	x_None	

5	Payment or honoraria for	_xNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	_xNone		
	testimony			
7	Support for attending	_xNone		
	meetings and/or travel			
8	Patents planned, issued or	x None		
	pending			
9	Participation on a Data	x None		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	x None		
	in other board, society,			
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	_xNone		
12	Receipt of equipment,	xNone		
	materials, drugs, medical			
	writing, gifts or other			
	services			
13	Other financial or non-	xNone		
	financial interests			
Plea	Please summarize the above conflict of interest in the following box:			
N	one			
- 1				

Date: July 6th	_
Your Name: Hui Sun	
Manuscript Title: Phase II study of sequential chemoradiotherapy with L-asparaginase, dexamethasone, ifosfami	ide
cisplatin, and etoposide (DICE-L) in the early stage of extranodal natural killer (NK)/T-cell lymphoma	
Manuscript number (if known):	_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	xNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	xNone	
3	Royalties or licenses	xNone	
4	Consulting fees	x_None	

5	Payment or honoraria for	_xNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	_xNone		
	testimony			
7	Support for attending	_xNone		
	meetings and/or travel			
8	Patents planned, issued or	x None		
	pending			
9	Participation on a Data	x None		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	x None		
	in other board, society,			
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	_xNone		
12	Receipt of equipment,	xNone		
	materials, drugs, medical			
	writing, gifts or other			
	services			
13	Other financial or non-	xNone		
	financial interests			
Plea	Please summarize the above conflict of interest in the following box:			
N	one			
- 1				

Date: <u>July 6th</u>	
Your Name: Fangfang Lv	
Manuscript Title: Phase II study of sequential ch	emoradiotherapy with L-asparaginase, dexamethasone, ifosfamide,
cisplatin, and etoposide (DICE-L) in the early sta	ge of extranodal natural killer (NK)/T-cell lymphoma
Manuscript number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	x_None	planning of the work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	xNone	
3	Royalties or licenses	xNone	
4	Consulting fees	x_None	

5	Payment or honoraria for	_xNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	_xNone		
	testimony			
7	Support for attending	_xNone		
	meetings and/or travel			
8	Patents planned, issued or	x None		
	pending			
9	Participation on a Data	x None		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	x None		
	in other board, society,			
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	_xNone		
12	Receipt of equipment,	xNone		
	materials, drugs, medical			
	writing, gifts or other			
	services			
13	Other financial or non-	xNone		
	financial interests			
Plea	Please summarize the above conflict of interest in the following box:			
N	one			
- 1				

Date: <u>July 6th</u>	
Your Name: Xi	aojian Liu
Manuscript Title: <u>F</u>	Phase II study of sequential chemoradiotherapy with L-asparaginase, dexamethasone, ifosfamide,
cisplatin, and etop	oside (DICE-L) in the early stage of extranodal natural killer (NK)/T-cell lymphoma
Manuscript number	er (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	xNone	pranning of the work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	xNone	
3	Royalties or licenses	x_None	
4	Consulting fees	x_None	

5	Payment or honoraria for	_xNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	_xNone		
	testimony			
7	Support for attending	_xNone		
	meetings and/or travel			
8	Patents planned, issued or	x None		
	pending			
9	Participation on a Data	x None		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	x None		
	in other board, society,			
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	_xNone		
12	Receipt of equipment,	xNone		
	materials, drugs, medical			
	writing, gifts or other			
	services			
13	Other financial or non-	xNone		
	financial interests			
		en		
Plea	Please summarize the above conflict of interest in the following box:			
N	one			
- 1				

Date: July 6th
Your Name: Junning Cao
Manuscript Title: Phase II study of sequential chemoradiotherapy with L-asparaginase, dexamethasone, ifosfamic
cisplatin, and etoposide (DICE-L) in the early stage of extranodal natural killer (NK)/T-cell lymphoma
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	xNone	pranning of the work
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	xNone	
3	Royalties or licenses	x_None	
4	Consulting fees	x_None	

5	Payment or honoraria for	_xNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	_xNone		
	testimony			
7	Support for attending	_xNone		
	meetings and/or travel			
8	Patents planned, issued or	x None		
	pending			
9	Participation on a Data	x None		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	x None		
	in other board, society,			
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	_xNone		
12	Receipt of equipment,	xNone		
	materials, drugs, medical			
	writing, gifts or other			
	services			
13	Other financial or non-	xNone		
	financial interests			
		en		
Plea	Please summarize the above conflict of interest in the following box:			
N	one			
- 1				

Date: July 6th	
Your Name:	Xiaonan Hong
Manuscript Title	e: Phase II study of sequential chemoradiotherapy with L-asparaginase, dexamethasone, ifosfamide,
cisplatin, and et	toposide (DICE-L) in the early stage of extranodal natural killer (NK)/T-cell lymphoma
Manuscript nun	nber (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	xNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	xNone	
3	Royalties or licenses	xNone	
4	Consulting fees	x_None	

5	Payment or honoraria for	_xNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	_xNone		
	testimony			
7	Support for attending	_xNone		
	meetings and/or travel			
8	Patents planned, issued or	x None		
	pending			
9	Participation on a Data	x None		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	x None		
	in other board, society,			
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	_xNone		
12	Receipt of equipment,	xNone		
	materials, drugs, medical			
	writing, gifts or other			
	services			
13	Other financial or non-	xNone		
	financial interests			
		en		
Plea	Please summarize the above conflict of interest in the following box:			
N	one			
- 1				

Date: July 6th
Your Name: Ye Guo
Manuscript Title: Phase II study of sequential chemoradiotherapy with L-asparaginase, dexamethasone, ifosfamid
cisplatin, and etoposide (DICE-L) in the early stage of extranodal natural killer (NK)/T-cell lymphoma
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	xNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	xNone	
3	Royalties or licenses	xNone	
4	Consulting fees	x_None	

5	Payment or honoraria for	_xNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	_xNone		
	testimony			
7	Support for attending	_xNone		
	meetings and/or travel			
8	Patents planned, issued or	x None		
	pending			
9	Participation on a Data	x None		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	x None		
	in other board, society,			
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	_xNone		
12	Receipt of equipment,	xNone		
	materials, drugs, medical			
	writing, gifts or other			
	services			
13	Other financial or non-	xNone		
	financial interests			
		en		
Plea	Please summarize the above conflict of interest in the following box:			
N	one			
- 1				

Date: <u>July 6th</u>		
Your Name: Xu	ejun Ma	
Manuscript Title: <u>P</u>	hase II study of sequential chemoradiotherapy with L-asparaginase, dexamethasone, ifosfamide,	
cisplatin, and etopo	oside (DICE-L) in the early stage of extranodal natural killer (NK)/T-cell lymphoma	
Manuscript numbe	r (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	xNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	xNone	
3	Royalties or licenses	x_None	
4	Consulting fees	x_None	

	Payment or honoraria for	_xNone	
le	ectures, presentations,		
S	speakers bureaus,		
n	manuscript writing or		
е	educational events		
6 P	Payment for expert	_xNone	
te	estimony		
7 S	Support for attending	_xNone	
n	neetings and/or travel		
8 P	Patents planned, issued or	x None	
	pending		
'	3		
9 P	Participation on a Data	x None	
	Safety Monitoring Board or		
	Advisory Board		
	eadership or fiduciary role	x None	
	n other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11 S	Stock or stock options	_xNone	
12 R	Receipt of equipment,	xNone	
n	naterials, drugs, medical		
	writing, gifts or other		
	services		
-	Other financial or non-	xNone	
fi	inancial interests		
•			
Dia	a anno mando a ele a ale ano	affice of incommunity about 11	austra kass.
Please	e summarize the above co	nflict of interest in the foll	owing box:
		nflict of interest in the foll	owing box:
Please		nflict of interest in the foll	owing box:
		nflict of interest in the foll	owing box:

Date: July 6th	
Your Name:	Qunling Zhang
Manuscript Title	e: Phase II study of sequential chemoradiotherapy with L-asparaginase, dexamethasone, ifosfamid
cisplatin, and et	oposide (DICE-L) in the early stage of extranodal natural killer (NK)/T-cell lymphoma
Manuscript num	ber (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	xNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	xNone	
3	Royalties or licenses	x_None	
4	Consulting fees	x_None	

5	Payment or honoraria for	_xNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_xNone	
	testimony		
7	Support for attending	x None	
	meetings and/or travel		
_	Detects of an and december	Name	
8	Patents planned, issued or	_xNone	
	pending		
0	5 5 .		
9	Participation on a Data	_xNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	xNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_xNone	
12	Receipt of equipment,	xNone	
	materials, drugs, medical		
	writing, gifts or other		
12	services Other financial or non-	y None	
13		xNone	
	financial interests		
DI	an arranguing tha abarra an	الماء عليه المعالمة المعالمة المعالمة المعالمة	auting have
riea	se summarize the above co	nilict of interest in the foll	owing bux:
IN	one		